Goldenwell Biotech (GWLL) Total Non-Current Liabilities (2022 - 2025)
Goldenwell Biotech (GWLL) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $125983.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Total Non-Current Liabilities rose 879.26% year-over-year to $125983.0, compared with a TTM value of $125983.0 through Sep 2025, up 879.26%, and an annual FY2024 reading of $82183.0, up 11.3% over the prior year.
- Total Non-Current Liabilities was $125983.0 for Q3 2025 at Goldenwell Biotech, down from $148883.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $148883.0 in Q2 2025 and bottomed at -$20366.0 in Q1 2024.
- Average Total Non-Current Liabilities over 4 years is $39129.5, with a median of $29126.0 recorded in 2022.
- The sharpest move saw Total Non-Current Liabilities plummeted 1544.4% in 2024, then surged 915.04% in 2025.
- Year by year, Total Non-Current Liabilities stood at $20000.0 in 2022, then soared by 269.18% to $73837.0 in 2023, then increased by 11.3% to $82183.0 in 2024, then soared by 53.3% to $125983.0 in 2025.
- Business Quant data shows Total Non-Current Liabilities for GWLL at $125983.0 in Q3 2025, $148883.0 in Q2 2025, and $84283.0 in Q1 2025.